The AIG, Illumina, Alphabet and Orient Life-backed cell therapy developer priced its shares at the bottom of the range to raise $70.6m.

Ping An's financial services spinoff raised $2.36bn in a US initial public offering that represented an exit for Bank of China, Cofco, SBI and several investment banks.

Novo, Bristol Myers-Squibb and Merck Group scored exits as the fibrosis and cancer drug developer priced its shares in the middle of the IPO's range.

The handcrafted product marketplace is set to list on TSE’s Mothers Market in a late November offering that will enable Globis, Japan Post, KDDI, Mitsui Fudosan, Mixi, SMBC and SBI to exit.

Several corporates are set to exit the financial services provider in the biggest IPO in history, while parent company Alibaba will buy about $7.5bn of shares.

The University of Oslo sensor software spinout has started trading on the Merkur Market, part of the Oslo Stock Exchange.

Alibaba´s financial subsidiary Ant has received approval from regulators which will allow a dual listing on the Shanghai and Hong Kong stock exchanges and enable it to raise up to $35bn at a reported valuation of $250bn.

Alibaba is set to retain a 32% stake in its financial services spinoff, which has secured regulatory permission for a dual listing that could value it at more than $250bn.

The immuno-oncology therapy developer filed to raise up to $50m, two years after securing money from investors including Biomed Realty and Alexandria Real Estate Equities.

The corporate-backed on-demand ride provider is reportedly looking at Hong Kong for a possible initial public offering, which could be preceded by more funding.